Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-02T19:55:45.364Z.
Calculation as of: 2026-10-02T19:55:45.364Z.
Quote observation: 2026-10-02T19:55:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 054a65786064a73545931b308e74131b250e2c5f6c2462854f5738f681d07736
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-08-13.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$63.17B
EV/EBIT Ratio
16.70x
TTM Avg
31.35x
3Y Avg
45.63x
5Y Avg
44.03x
Market Cap
$53.70B
EV/EBIT Ratio
22.50x
TTM Avg
22.85x
3Y Avg
24.17x
5Y Avg
35.02x
Market Cap
$49.07B
EV/EBIT Ratio
25.62x
TTM Avg
28.52x
3Y Avg
29.75x
5Y Avg
32.11x
Market Cap
$48.68B
EV/EBIT Ratio
31.63x
TTM Avg
25.97x
3Y Avg
29.21x
5Y Avg
30.17x
Market Cap
$47.49B
EV/EBIT Ratio
30.31x
TTM Avg
26.77x
3Y Avg
27.54x
5Y Avg
27.94x
Market Cap
$45.97B
EV/EBIT Ratio
29.85x
TTM Avg
27.26x
3Y Avg
57.22x
5Y Avg
50.20x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Natera, Inc. (NTRA) | $58.64B | N/A | N/A | N/A | N/A |
| Cencora, Inc. (COR)vs › | $60.25B | 15.95x | 18.13x | 18.25x | 16.08x |
| Boston Scientific Corporation (BSX)vs › | $63.17B | 16.70x | 31.35x | 45.63x | 44.03x |
| Cardinal Health, Inc. (CAH)vs › | $53.70B | 22.50x | 22.85x | 24.17x | 35.02x |
| Edwards Lifesciences Corporation (EW)vs › | $49.07B | 25.62x | 28.52x | 29.75x | 32.11x |
| Becton, Dickinson and Company (BDX)vs › | $48.68B | 31.63x | 25.97x | 29.21x | 30.17x |
| Agilent Technologies, Inc. (A)vs › | $47.49B | 30.31x | 26.77x | 27.54x | 27.94x |
| Humana Inc. (HUM)vs › | $46.78B | 26.77x | 26.45x | 21.09x | 19.84x |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.97B | 29.85x | 27.26x | 57.22x | 50.20x |
| Cigna Corporation (CI)vs › | $71.56B | 9.95x | 10.74x | 12.27x | 12.87x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2015-08-13 | 384.95x |
| 2015-08-12 | 406.08x |
| 2015-08-11 | 414.64x |
| 2015-08-10 | 427.75x |
| 2015-08-07 | 425.08x |
| 2015-08-06 | 445.68x |
| 2015-08-05 | 436.58x |
| 2015-08-04 | 428.82x |
| 2015-08-03 | 419.73x |
| 2015-07-31 | 452.63x |
| 2015-07-30 | 453.70x |
| 2015-07-29 | 455.84x |
| 2015-07-28 | 451.29x |
| 2015-07-27 | 450.22x |
| 2015-07-24 | 482.86x |
| 2015-07-23 | 514.97x |
| 2015-07-22 | 524.33x |
| 2015-07-21 | 519.78x |
| 2015-07-20 | 541.99x |
| 2015-07-17 | 527.27x |
| 2015-07-16 | 554.02x |
| 2015-07-15 | 517.91x |
| 2015-07-14 | 521.92x |
| 2015-07-13 | 532.89x |
| 2015-07-10 | 550.55x |
| 2015-07-09 | 537.17x |
| 2015-07-08 | 543.06x |
| 2015-07-07 | 557.23x |
| 2015-07-06 | 557.23x |
| 2015-07-02 | 577.03x |
| 2015-07-01 | 450.22x |
